These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 26864382)

  • 1. Identification of a founder BRCA1 mutation in the Moroccan population.
    Quiles F; Teulé À; Martinussen Tandstad N; Feliubadaló L; Tornero E; Del Valle J; Menéndez M; Salinas M; Wethe Rognlien V; Velasco A; Izquierdo A; Capellá G; Brunet J; Lázaro C
    Clin Genet; 2016 Oct; 90(4):361-5. PubMed ID: 26864382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased prevalence of the founder BRCA1 c.5309G>T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling.
    Melki R; Melloul M; Aissaoui S; El Harroudi T; Boukhatem N
    BMC Cancer; 2023 Apr; 23(1):339. PubMed ID: 37055759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of specific and recurrent/founder pathogenic variants in BRCA genes in breast and ovarian cancer in North Africa.
    ElBiad O; Laraqui A; El Boukhrissi F; Mounjid C; Lamsisi M; Bajjou T; Elannaz H; Lahlou AI; Kouach J; Benchekroune K; Oukabli M; Chahdi H; Ennaji MM; Tanz R; Sbitti Y; Ichou M; Ennibi K; Badaoui B; Sekhsokh Y
    BMC Cancer; 2022 Feb; 22(1):208. PubMed ID: 35216584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients.
    Meng H; Yao L; Yuan H; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Int J Cancer; 2020 Jun; 146(11):3044-3052. PubMed ID: 31957001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
    Cini G; Mezzavilla M; Della Puppa L; Cupelli E; Fornasin A; D'Elia AV; Dolcetti R; Damante G; Bertok S; Miolo G; Maestro R; de Paoli P; Amoroso A; Viel A
    BMC Med Genet; 2016 Feb; 17():11. PubMed ID: 26852130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population.
    Nielsen HR; Nilbert M; Petersen J; Ladelund S; Thomassen M; Pedersen IS; Hansen TV; Skytte AB; Borg Å; Therkildsen C
    Fam Cancer; 2016 Oct; 15(4):507-12. PubMed ID: 26833046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation screening of the BRCA1 gene in early onset and familial breast/ovarian cancer in Moroccan population.
    Laraqui A; Uhrhammer N; Lahlou-Amine I; El Rhaffouli H; El Baghdadi J; Dehayni M; Moussaoui RD; Ichou M; Sbitti Y; Al Bouzidi A; Amzazi S; Bignon YJ
    Int J Med Sci; 2013; 10(1):60-7. PubMed ID: 23289006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.
    Bergman A; Einbeigi Z; Olofsson U; Taib Z; Wallgren A; Karlsson P; Wahlström J; Martinsson T; Nordling M
    Eur J Hum Genet; 2001 Oct; 9(10):787-93. PubMed ID: 11781691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy.
    Papi L; Putignano AL; Congregati C; Zanna I; Sera F; Morrone D; Falchetti M; Turco MR; Ottini L; Palli D; Genuardi M
    Breast Cancer Res Treat; 2009 Oct; 117(3):497-504. PubMed ID: 18821011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?
    Russo A; Calò V; Bruno L; Schirò V; Agnese V; Cascio S; Foddai E; Fanale D; Rizzo S; Di Gaudio F; Gulotta E; Surmacz E; Di Fede G; Bazan V
    Breast Cancer Res Treat; 2009 Jan; 113(1):67-70. PubMed ID: 18228134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of the recurrent c.1310_1313delAAGA BRCA2 mutation in the North-East of Morocco and implication for hereditary breast-ovarian cancer prevention and control.
    Laarabi FZ; Ratbi I; Elalaoui SC; Mezzouar L; Doubaj Y; Bouguenouch L; Ouldim K; Benjaafar N; Sefiani A
    BMC Res Notes; 2017 Jun; 10(1):188. PubMed ID: 28577564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.
    Vézina H; Durocher F; Dumont M; Houde L; Szabo C; Tranchant M; Chiquette J; Plante M; Laframboise R; Lépine J; Nevanlinna H; Stoppa-Lyonnet D; Goldgar D; Bridge P; Simard J
    Hum Genet; 2005 Jul; 117(2-3):119-32. PubMed ID: 15883839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
    Pertesi M; Konstantopoulou I; Yannoukakos D
    Clin Genet; 2011 Oct; 80(4):375-82. PubMed ID: 20840220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haplotype of the C61G BRCA1 mutation in Polish and Jewish individuals.
    Kaufman B; Laitman Y; Gronwald J; Lubinski J; Friedman E
    Genet Test Mol Biomarkers; 2009 Aug; 13(4):465-9. PubMed ID: 19594371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The limited spectrum of pathogenic BRCA1 and BRCA2 mutations in the French Canadian breast and breast-ovarian cancer families, a founder population of Quebec, Canada].
    Tonin PN
    Bull Cancer; 2006 Sep; 93(9):841-6. PubMed ID: 16980226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of an Italian founder mutation in the RING-finger domain of BRCA1.
    Caleca L; Putignano AL; Colombo M; Congregati C; Sarkar M; Magliery TJ; Ripamonti CB; Foglia C; Peissel B; Zaffaroni D; Manoukian S; Tondini C; Barile M; Pensotti V; Bernard L; Papi L; Radice P
    PLoS One; 2014; 9(2):e86924. PubMed ID: 24516540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect.
    Muller D; Bonaiti-Pellié C; Abecassis J; Stoppa-Lyonnet D; Fricker JP
    Fam Cancer; 2004; 3(1):15-20. PubMed ID: 15131401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history.
    Anagnostopoulos T; Pertesi M; Konstantopoulou I; Armaou S; Kamakari S; Nasioulas G; Athanasiou A; Dobrovic A; Young MA; Goldgar D; Fountzilas G; Yannoukakos D
    Breast Cancer Res Treat; 2008 Jul; 110(2):377-85. PubMed ID: 17902052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
    Dodova RI; Mitkova AV; Dacheva DR; Hadjo LB; Vlahova AI; -Hadjieva MST; Valev SS; Caulevska MM; Popova SD; Popov IE; Dikov TI; Sedloev TA; Ionkov AS; Timcheva KV; Christova SL; Kremensky IM; Mitev VI; Kaneva RP
    BMC Cancer; 2015 Jul; 15():523. PubMed ID: 26183948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of founder mutations to early-onset breast cancer in French-Canadian women.
    Ghadirian P; Robidoux A; Zhang P; Royer R; Akbari M; Zhang S; Fafard E; Costa M; Martin G; Potvin C; Patocskai E; Larouche N; Younan R; Nassif E; Giroux S; Narod SA; Rousseau F; Foulkes WD
    Clin Genet; 2009 Nov; 76(5):421-6. PubMed ID: 19863560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.